Hemophilia B Leyden and once mysterious cis-regulatory mutations
- PMID: 24138812
- DOI: 10.1016/j.tig.2013.09.007
Hemophilia B Leyden and once mysterious cis-regulatory mutations
Abstract
Hemophilia B is a classic, monogenic blood clotting disease caused by mutations in the coagulation factor IX (F9) locus. Although interpreting mutations within the gene itself has been relatively straightforward, ascribing molecular mechanisms to the complete suite of mutations within the promoter region has proven somewhat difficult and has only recently been achieved. These mutations, which are clustered at discrete transcription factor binding sites, dynamically alter the developmental expression of F9 in different ways. They illustrate how single-nucleotide mutations in cis-regulatory regions can have drastic ramifications for the control of gene expression and in some instances be causative of disease. Here we present the human F9 promoter as a model example for which saturation mutation mapping has revealed the mechanisms of its regulation. Moreover, we suggest that the growing number of genome-wide studies of transcription factor activity will accelerate both the discovery and understanding of regulatory polymorphisms and mutations.
Keywords: SNPs; gene regulation; hemophilia; promoter mutations; regulatory mutations.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B.Nature. 1990 May 31;345(6274):444-6. doi: 10.1038/345444a0. Nature. 1990. PMID: 2342576
-
Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene.Blood Coagul Fibrinolysis. 1994 Jun;5(3):341-8. Blood Coagul Fibrinolysis. 1994. PMID: 8075306
-
Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation.Nat Genet. 1993 Feb;3(2):175-9. doi: 10.1038/ng0293-175. Nat Genet. 1993. PMID: 8499951
-
[The current feature of the study on human coagulation factor IX mutant].Yi Chuan. 2005 Sep;27(5):833-8. Yi Chuan. 2005. PMID: 16257919 Review. Chinese.
-
The Canadian "National Program for hemophilia mutation testing" database: a ten-year review.Am J Hematol. 2013 Dec;88(12):1030-4. doi: 10.1002/ajh.23557. Epub 2013 Sep 9. Am J Hematol. 2013. PMID: 23913812 Review.
Cited by
-
Deep molecular learning of transcriptional control of a synthetic CRE enhancer and its variants.iScience. 2023 Dec 15;27(1):108747. doi: 10.1016/j.isci.2023.108747. eCollection 2024 Jan 19. iScience. 2023. PMID: 38222110 Free PMC article.
-
Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice.Hamostaseologie. 2022 Dec;42(6):390-399. doi: 10.1055/a-1945-9429. Epub 2022 Dec 22. Hamostaseologie. 2022. PMID: 36549291 Free PMC article. Review.
-
Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion.Proc Natl Acad Sci U S A. 2021 Oct 19;118(42):e2110887118. doi: 10.1073/pnas.2110887118. Proc Natl Acad Sci U S A. 2021. PMID: 34649996 Free PMC article.
-
The Molecular Basis of FIX Deficiency in Hemophilia B.Int J Mol Sci. 2022 Mar 2;23(5):2762. doi: 10.3390/ijms23052762. Int J Mol Sci. 2022. PMID: 35269902 Free PMC article. Review.
-
First case report of hemophilia B Leyden in Japan.Int J Hematol. 2017 Jul;106(1):135-137. doi: 10.1007/s12185-017-2194-4. Epub 2017 Feb 7. Int J Hematol. 2017. PMID: 28168417
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous